Patent ID: 7611858

Claim:
A method for determining the presence of traumatic brain injury (TBI), comprising analyzing for cannabinoid receptor type 1 (CB1) extracellular N-terminal and C-terminal biomarker proteins selected from the group consisting of 40-42 kDa, 62-64 kDa, 120-130 kDa, and >260 kDa monomeric or multimeric CB1 complexes in a cerebral spinal fluid (CSF), hippocampal, cortical or serum sample from a subject suspected of having TBI within and up to about 14 days from the TBI; and comparing levels of the biomarker proteins in a comparable sample from a normal subject; wherein levels of extracellular N-terminal biomarker CB1 proteins are decreased and levels of the C-terminal biomarker CB1 proteins are increased in the sample of the subject suspected of having TBI compared to comparable samples from normal subjects.